News Archive

October 2019

• Press Release Oct 10, 2019

  Novartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis

  New two-year data compare the effects of Cosentyx (secukinumab) treatment in psoriatic arthritis patients with and without enthesitis, a manifestation described in 30-50% of patients [1] Results…
• Featured News Oct 10, 2019

  World Sight Day 2019

• Press Release Oct 09, 2019

  Novartis real-world evidence confirms high efficacy, long-term response and favorable safety profile of Cosentyx® in clinical practice

  Data from five real-world evidence (RWE) and observational studies being conducted in North America, Latin America and Europe provide extensive cumulative insights for Cosentyx (secukinumab) clinical…
• 
  Story Oct 08, 2019 Patient Perspectives

  Lessons from a blind chef

  Christine Hà lost her vision at a young age – and went on to become an award-winning chef.

• Press Release Oct 08, 2019

  Novartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mg

  Results from a Phase IIb dose-finding study show an average complete response rate of 42% for doses 240 mg and 72 mg ligelizumab at Week 12 compared with 26% for those taking 300 mg Xolair’s dose (…
• Key Release Oct 08, 2019

  Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept

   In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of…
• 
  Story Oct 07, 2019 People and Culture

  Oncology Careers: Life Changing Purpose

• Press Release Oct 05, 2019

  AveXis presents updated STRONG data at WMS

  Older patients (≥ 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follow-up…
• 
  Story Oct 03, 2019 Discovery

  Women in Science: Lauren Abrey

  Learn about the career of our Global Medical Affairs Head for Solid Tumors and Rare Diseases.

• Key Release Oct 02, 2019

  Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum

  Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)[1] Novartis plans FDA submission…
• Press Release Oct 01, 2019

  Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence

  Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercializedNovartis to establish…
• Featured News Oct 01, 2019

  Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence